28 Jan The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion
On Wednesday night the New England Journal of Medicine published a study showing that a new, DNA-sequencing based blood test provides a dramatic improvement in accuracy at screening for Down syndrome and a second, deadly disorder. That could open up a $6 billion market to...